Malignant Lung Neoplasm — Trials

Malignant Lung Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,648
Recruiting: 1,431
Ph III recruiting: 179
Growth YoY: +7.9%
Industry share: 37%
Top sponsor: AstraZeneca
Termination share: 34.8%
Trials / 1,000 deaths: 20.1 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,489)

clinicaltrialsPublishedShowing 2,501–2,503 of 2,503 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00179699	Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer	terminated	Phase 1	40	Celgene CorporationINDUSTRY	1	Nov 7, 2005	clinicaltrials
NCT00040560	Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer	unknown	Phase 1	—	CopharosINDUSTRY	1	Jun 24, 2005